| dc.contributor.author | De La Hoz, Franklin José Espitia | spa |
| dc.date.accessioned | 2022-01-14 00:00:00 | |
| dc.date.available | 2022-01-14 00:00:00 | |
| dc.date.issued | 2022-01-14 | |
| dc.format.mimetype | application/pdf | spa |
| dc.identifier.doi | 10.32997/rcb-2022-3223 | |
| dc.identifier.eissn | 2389-7252 | |
| dc.identifier.issn | 2215-7840 | |
| dc.identifier.url | https://doi.org/10.32997/rcb-2022-3223 | |
| dc.language.iso | spa | spa |
| dc.publisher | Universidad de Cartagena | spa |
| dc.relation.bitstream | https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/3223/3088 | |
| dc.relation.citationedition | Núm. 1 , Año 2022 | spa |
| dc.relation.citationendpage | 79 | |
| dc.relation.citationissue | 1 | spa |
| dc.relation.citationstartpage | 66 | |
| dc.relation.citationvolume | 11 | spa |
| dc.relation.ispartofjournal | Revista Ciencias Biomédicas | spa |
| dc.relation.references | Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol. 1993; 168(3 Pt 1):772-80. http://dx.doi.org/10.1016/s0002-9378(12)90817-0 | spa |
| dc.relation.references | Jenabi E, Shobeiri F, Hazavehei SM, Roshanaei G. Assessment of Questionnaire Measuring Quality of Life in Menopausal Women: A Systematic Review. Oman Med J. 2015; 30(3):151-6. http://dx.doi.org/10.5001/omj.2015.34 | spa |
| dc.relation.references | Li C, Samsioe G, Borgfeldt C, Lidfeldt J, Agardh CD, Nerbrand C. Menopause-related symptoms: what are the background factors? A prospective population-based cohort study of Swedish women (The Women's Health in Lund Area study). Am J Obstet Gynecol. 2003; 189(6):1646-53. http://dx.doi.org/10.1016/s0002-9378(03)00872-x | spa |
| dc.relation.references | Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation. Obstet Gynecol Clin North Am. 2011; 38(3):489-501. http://dx.doi.org/10.1016/j.ogc.2011.05.006 | spa |
| dc.relation.references | Espitia De la Hoz FJ. Prevalence of genitourinary syndrome of menopause and impact on sexuality of women in Quindío (Colombia), 2013-2016. Rev Colomb Obstet Ginecol. 2018; 69(4):249-59. https://doi.org/10.18597/rcog.3111 | spa |
| dc.relation.references | Warren MP, Halpert S. Hormone replacement therapy: controversies, pros and cons. Best Pract Res Clin Endocrinol Metab. 2004; 18(3):317-32. https://doi.org/10.1016/j.beem.2004.02.005 | spa |
| dc.relation.references | Björn I, Bäckström T, Lalos A, Sundström-Poromaa I. Adverse mood effects during postmenopausal hormone treatment in relation to personality traits. Climacteric. 2006; 9(4):290-7. https://doi.org/10.1080/13697130600865766 | spa |
| dc.relation.references | Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001; 75(6):1065-79. https://doi.org/10.1016/s0015-0282(01)01791-5 | spa |
| dc.relation.references | Johansen N, Liavaag AH, Tanbo TG, Dahl AA, Pripp AH, Michelsen TM. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy. Gynecol Oncol. 2016; 140(1):101-6. https://doi.org/10.1016/j.ygyno.2015.11.016 | spa |
| dc.relation.references | Hodis HN, Mack WJ. Hormone replacement therapy and the association with coronary heart disease and overall mortality: clinical application of the timing hypothesis. J Steroid Biochem Mol Biol. 2014; 142:68-75. https://doi.org/10.1016/j.jsbmb.2013.06.011 | spa |
| dc.relation.references | The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017; 24(7):728-53. https://doi.org/10.1097/GME.0000000000000921 | spa |
| dc.relation.references | Preston RA. Comparative effects of conventional vs. novel hormone replacement therapy on blood pressure in postmenopausal women. Climacteric. 2009; 12 Suppl 1:66-70. https://doi.org/10.1080/13697130902775788 | spa |
| dc.relation.references | Kenemans P. Tibolone: how does its mechanism of action translate into clinical effects. Maturitas. 2004; 48 Suppl 1:S1-3. https://doi.org/10.1016/j.maturitas.2004.02.014 | spa |
| dc.relation.references | Wang PH, Horng HC, Cheng MH, Chao HT, Chao KC. Standard and low-dose hormone therapy for postmenopausal women--focus on the breast. Taiwan J Obstet Gynecol. 2007; 46(2):127-34. https://doi.org/10.1016/S1028-4559(07)60006-0 | spa |
| dc.relation.references | Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab. 2002; 87(1):16-23. https://doi.org/10.1210/jcem.87.1.8141 | spa |
| dc.relation.references | Timmer CJ, Verheul HA, Doorstam DP. Pharmacokinetics of tibolone in early and late postmenopausal women. Br J Clin Pharmacol. 2002; 54(2):101-6. https://doi.org/10.1046/j.1365-2125.2002.01619.x | spa |
| dc.relation.references | Crona N, Samsioe G, Lindberg UB, Silfverstolpe G. Treatment of climacteric complaints with Org OD 14: a comparative study with oestradiol valerate and placebo. Maturitas. 1988; 9(4):303-8. https://doi.org/10.1016/0378-5122(88)90095-3 | spa |
| dc.relation.references | Kicovic PM, Cortés-Prieto J, Luisi M, Milojevic S, Franchi F. Placebo-controlled cross-over study of effects of Org OD 14 in menopausal women. Reproduccion. 1982; 6(2):81-91. | spa |
| dc.relation.references | Punnonen R, Liukko P, Cortes-Prieto J, Eydam F, Milojevic S, Trévoux R, et al. Multicentre study of effects of Org OD 14 on endometrium, vaginal cytology and cervical mucus in post-menopausal and oophorectomized women. Maturitas. 1984; 5(4):281-6. https://doi.org/10.1016/0378-5122(84)90023-9 | spa |
| dc.relation.references | de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone. Steroids. 2003; 68(1):21-30. https://doi.org/10.1016/s0039-128x(02)00112-5 | spa |
| dc.relation.references | Jelinek J, Kappen A, Schönbaum E, Lomax P. A primate model of human postmenopausal hot flushes. J Clin Endocrinol Metab. 1984; 59(6):1224-8. https://doi.org/10.1210/jcem-59-6-1224 | spa |
| dc.relation.references | Landgren MB, Helmond FA, Engelen S. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. Maturitas. 2005; 50(3):222-30. https://doi.org/10.1016/j.maturitas.2004.06.001 | spa |
| dc.relation.references | Espitia De La Hoz FJ. Terapia de reemplazo hormonal combinada con testosterona para el tratamiento del trastorno del deseo sexual hipoactivo en mujeres en climaterio. Arch Med (Manizales) 2020; 20(1):71-85. https://doi.org/10.30554/archmed.20.1.3388.2020 | spa |
| dc.relation.references | Verheul HA, Blok LJ, Burger CW, Hanifi-Moghaddam P, Kloosterboer HJ. Levels of tibolone and estradiol and their nonsulfated and sulfated metabolites in serum, myometrium, and vagina of postmenopausal women following treatment for 21 days with tibolone, estradiol, or estradiol plus medroxyprogestrone acetate. Reprod Sci. 2007; 14(2):160-8. https://doi.org/10.1177/1933719106298684 | spa |
| dc.relation.references | Albertazzi P, Di Micco R, Zanardi E. Tibolone: a review. Maturitas. 1998; 30(3):295-305. https://doi.org/10.1016/s0378-5122(98)00059-0 | spa |
| dc.relation.references | Formoso G, Perrone E, Maltoni S, Balduzzi S, D'Amico R, Bassi C, et al. Short and long term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2012; (2):CD008536. https://doi.org/10.1002/14651858.CD008536.pub2 | spa |
| dc.relation.references | Moore RA. Livial: a review of clinical studies. Br J Obstet Gynaecol. 1999; 106 Suppl 19:1-21. | spa |
| dc.relation.references | Ziaei S, Moghasemi M, Faghihzadeh S. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climacteric. 2010; 13(2):147-56. https://doi.org/10.1080/13697130903009195 | spa |
| dc.relation.references | Vos RM, Krebbers SF, Verhoeven CH, Delbressine LP. The in vivo human metabolism of tibolone. Drug Metab Dispos. 2002; 30(2):106-12. https://doi.org/10.1124/dmd.30.2.106 | spa |
| dc.relation.references | Palacios S, Menendez C, Jurado AR, Castaño R, Vargas JC. Changes in sex behaviour after menopause: effects of tibolone. Maturitas. 1995; 22(2):155-61. https://doi.org/10.1016/0378-5122(95)00930-j | spa |
| dc.relation.references | Kökçü A, Cetinkaya MB, Yanik F, Alper T, Malatyalioğlu E. The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. Maturitas. 2000; 36(1):75-80. https://doi.org/10.1016/s0378-5122(00)00134-1 | spa |
| dc.relation.references | Omu F, Elbiaa A, Ghafour A, Gadalla I, Omu A. Beneficial Effects of Tibolone on Sexual Dys-function in Women with Premature Ovarian Failure (POF). Health. 2016; 8(9):857-67. https://doi.org/10.4236/health.2016.89090 | spa |
| dc.relation.references | Dören M, Rübig A, Coelingh Bennink HJ, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril. 2001; 75(3):554-9. https://doi.org/10.1016/s0015-0282(00)01768-4 | spa |
| dc.relation.references | van der Stege JG, Groen H, van Zadelhoff SJ, Lambalk CB, Braat DD, van Kasteren YM, et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause. 2008; 15(1):23-31. https://doi.org/10.1097/gme.0b013e3180f6108c | spa |
| dc.relation.references | Drillich A, Davis SR. Androgen therapy in women: what we think we know. Exp Gerontol. 2007; 42(6):457-62. https://doi.org/10.1016/j.exger.2007.02.005 | spa |
| dc.relation.references | Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 2001; 76(1-5):231-8. https://doi.org/10.1016/s0960-0760(01)00044-9 | spa |
| dc.relation.references | Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric. 2001; 4(1):28-41. | spa |
| dc.relation.references | Wu MH, Pan HA, Wang ST, Hsu CC, Chang FM, Huang KE. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric. 2001; 4(4):314-9. | spa |
| dc.relation.references | Valdivia I, Campodónico I, Tapia A, Capetillo M, Espinoza A, Lavín P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril. 2004; 81(3):617-23. https://doi.org/10.1016/j.fertnstert.2003.07.041 | spa |
| dc.relation.references | Wender MC, Edelweiss MI, Campos LS, de Castro JA, Spritzer PM. Endometrial assessment in women using tibolone or placebo: 1-year randomized trial and 2-year observational study. Menopause. 2004; 11(4):423-9. https://doi.org/10.1097/01.gme.0000109315.11228.ac | spa |
| dc.relation.references | Kenemans P, Speroff L; International Tibolone Consensus Group. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas. 2005; 51(1):21-8. https://doi.org/10.1016/j.maturitas.2005.02.011 | spa |
| dc.relation.references | Roux C, Pelissier C, Fechtenbaum J, Loiseau-Peres S, Benhamou CL. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos Int. 2002; 13(3):241-8. https://doi.org/10.1007/s001980200021 | spa |
| dc.relation.references | Lippuner K, Haenggi W, Birkhaeuser MH, Casez JP, Jaeger P. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone. J Bone Miner Res. 1997; 12(5):806-12. https://doi.org/10.1359/jbmr.1997.12.5.806 | spa |
| dc.relation.references | Rymer J, Robinson J, Fogelman I. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric. 2002; 5(4):390-8. | spa |
| dc.relation.references | Morris EP, Denton ER, Robinson J, MacDonald LM, Rymer JM. High resolution ultrasound assessment of the carotid artery: its relevance in postmenopausal women and the effects of tibolone on carotid artery ultrastructure. Climacteric. 1999; 2(1):13-20. https://doi.org/10.3109/13697139909025558 | spa |
| dc.relation.references | Cagnacci A, Baldassari F, Arangino S, Alessandrini C, Volpe A. Administration of tibolone decreases 24 h heart rate but not blood pressure of post-menopausal women. Maturitas. 2004; 48(2):155-60. https://doi.org/10.1016/j.maturitas.2003.08.011 | spa |
| dc.relation.references | Ostberg JE, Damjanovic T, Dimkovic N, Byrne D, Mikhailidis DP, Prelevic GM. Effect of tibolone on markers of cardiovascular disease risk in postmenopausal women undergoing hemodialysis: a pilot study. Fertil Steril. 2004; 81(6):1624-31. https://doi.org/10.1016/j.fertnstert.2003.11.033 | spa |
| dc.relation.references | Christodoulakos GE, Lambrinoudaki IV, Panoulis CP, Papadias CA, Kouskouni EE, Creatsas GC. Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women. Gynecol Endocrinol. 2004; 18(5):244-57. https://doi.org/10.1080/09513590410001715207 | spa |
| dc.relation.references | Vassalle C, Cicinelli E, Lello S, Mercuri A, Battaglia D, Maffei S. Effects of menopause and tibolone on different cardiovascular biomarkers in healthy women. Gynecol Endocrinol. 2011; 27(3):163-9. https://doi.org/10.3109/09513590.2010.488770. | spa |
| dc.relation.references | von Eckardstein A, Schmiddem K, Hövels A, Gülbahçe E, Schuler-Lüttmann S, Elbers J, et al. Lowering of HDL cholesterol in post-menopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity. Atherosclerosis. 2001; 159(2):433-9. https://doi.org/10.1016/s0021-9150(01)00522-6 | spa |
| dc.relation.references | Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, Garibaldi S, et al. Tibolone activates nitric oxide synthesis in human endothelial cells. J Clin Endocrinol Metab. 2004; 89(9):4594-600. https://doi.org/10.1210/jc.2003-032189. | spa |
| dc.relation.references | Cicinelli E, Ignarro LJ, Galantino P, Pinto V, Barba B, Schonauer S. Effects of tibolone on plasma levels of nitric oxide in postmenopausal women. Fertil Steril. 2002; 78(3):464-8. https://doi.org/10.1016/s0015-0282(02)03295-8 | spa |
| dc.relation.references | Simoncini T, Genazzani AR. Tibolone inhibits leukocyte adhesion molecule expression in human endothelial cells. Mol Cell Endocrinol. 2000; 162(1-2):87-94. https://doi.org/10.1016/s0303-7207(00)00206-9 | spa |
| dc.relation.references | Aguayo-Cerón KA, Morales-González JA, Gutiérrez-Iglesias G, Parra-Barrera A, Jiménez-Zamarripa CA, Ocharán-Hernández ME, et al. Efecto Regulador de Tibolona sobre la Actividad Antiinflamatoria del Macrófago. Revista Mexicana De Ingeniería Biomédica. 2019; 40(3):1-10. https://doi.org/10.17488/RMIB.40.3.1 | spa |
| dc.relation.references | North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012; 19(3):257-71. https://doi.org/10.1097/gme.0b013e31824b970a | spa |
| dc.relation.references | Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100(11):3975-4011. https://doi.org/10.1210/jc.2015-2236 | spa |
| dc.relation.references | Eilertsen AL, Qvigstad E, Andersen TO, Sandvik L, Sandset PM. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. Maturitas. 2006; 55(3):278-87. https://doi.org/10.1016/j.maturitas.2006.04.012 | spa |
| dc.relation.references | Appt SE, Törmälä R, Franke AA, Mikkola TS, Tikkanen MJ, Ylikorkala O, et al. Soy-tibolone combination - effect on lipids in postmenopausal monkeys and women. Maturitas. 2008; 60(3-4):216-22. https://doi.org/10.1016/j.maturitas.2008.06.003 | spa |
| dc.relation.references | Bjarnason NH, Bjarnason K, Haarbo J, Bennink HJ, Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab. 1997; 82(6):1752-6. https://doi.org/10.1210/jcem.82.6.3995 | spa |
| dc.relation.references | Register TC, Wagner JD, Zhang L, Hall J, Clarkson TB. Effects of tibolone and conventional hormone replacement therapies on arterial and hepatic cholesterol accumulation and on circulating endothelin-1, vascular cell adhesion molecule-1, and E-selectin in surgically menopausal monkeys. Menopause. 2002; 9(6):411-21. https://doi.org/10.1097/00042192-200211000-00006 | spa |
| dc.relation.references | Stark J, Varbiro S, Sipos M, Tulassay Z, Sara L, Adler I, et al. Antioxidant effect of the active metabolites of tibolone. Gynecol Endocrinol. 2015; 31(1):31-5. https://doi.org/10.3109/09513590.2014.943727 | spa |
| dc.relation.references | Dubey RK, Gillespie DG, Grögli M, Kloosterboer HJ, Imthurn B. Tibolone and its metabolites induce antimitogenesis in human coronary artery smooth muscle cells: role of estrogen, progesterone, and androgen receptors. J Clin Endocrinol Metab. 2004; 89(2):852-9. https://doi.org/10.1210/jc.2003-031272 | spa |
| dc.relation.references | Castelo-Branco C, Casals E, Figueras F, Sanjuan A, Vicente JJ, Balasch J, et al. Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AI and B. Menopause. 1999 Summer; 6(2):92-7. | spa |
| dc.relation.references | Nathorst-Böös J, Hammar M. Effect on sexual life--a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas. 1997; 26(1):15-20. https://doi.org/10.1016/s0378-5122(96)01069-9 | spa |
| dc.relation.references | Espitia De La Hoz FJ, Marega O, Orozco Gallego H. Manejo farmacológico de la disfunción sexual femenina en la postmenopausia, con tibolona y testosterona. Revista de Sexología. 2016; 5(2):9-18. | spa |
| dc.relation.references | Nijland EA, Weijmar Schultz WC, Nathorst-Boös J, Helmond FA, Van Lunsen RH, Palacios S, et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med. 2008; 5(3):646-56. https://doi.org/10.1111/j.1743-6109.2007.00726.x | spa |
| dc.relation.references | Baños G, Guarner V, Pérez-Torres I. Sex steroid hormones, cardiovascular diseases and the metabolic syndrome. Cardiovasc Hematol Agents Med Chem. 2011; 9(3):137-46. https://doi.org/10.2174/187152511797037547 | spa |
| dc.relation.references | Kotani K, Sahebkar A, Serban C, Andrica F, Toth PP, Jones SR, et al. Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. Atherosclerosis. 2015; 242(1):87-96. https://doi.org/10.1016/j.atherosclerosis.2015.06.056 | spa |
| dc.relation.references | Parkin DE, Smith D, Al Azzawi F, Lindsay R, Hart DM. Effects of long-term Org OD 14 administration on blood coagulation in climacteric women. Maturitas. 1987; 9(1):95-101. https://doi.org/10.1016/0378-5122(87)90057-0 | spa |
| dc.relation.references | Tax L, Kicovic PM. Clinical profile of Org OD14. Maturitas 1984; 6:196. | spa |
| dc.relation.references | Yates RW, Richards A, McEwan HP, Coutts JR, Walker ID, Davidson JF. Hormonal and fibrinolytic effects of the synthetic steroid Org OD14 in menopausal women. Maturitas 1984; 6:210. | spa |
| dc.relation.references | Archer DF, Hendrix S, Gallagher JC, Rymer J, Skouby S, Ferenczy A, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab. 2007; 92(3):911-8. https://doi.org/10.1210/jc.2006-2207. | spa |
| dc.relation.references | Bundred NJ, Kenemans P, Yip CH, Beckmann MW, Foidart JM, Sismondi P, et al. Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy. Breast Cancer Res. 2012; 14(1):R13. https://doi.org/10.1186/bcr3097. | spa |
| dc.relation.references | Bringer J, Raingeard I, Lefebre P, Renard E. Ménopause. Vers un traitement «a la carte». Ann Endocrinol. 2003; 64:337-44. | spa |
| dc.relation.references | McKinney KA, Thompson W. A practical guide to prescribing hormone replacement therapy. Drugs. 1998; 56:49-57. | spa |
| dc.relation.references | Modelska K, Cummings S. Female sexual dysfunction in postmenopausal women: systematic review of placebo-controlled trials. Am J Obstet Gynecol. 2003; 188(1):286-93. https://doi.org/10.1067/mob.2003.117 | spa |
| dc.rights | Franklin José Espitia De La Hoz - 2022 | spa |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.rights.coar | http://purl.org/coar/access_right/c_abf2 | spa |
| dc.rights.creativecommons | Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. | spa |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/4.0 | spa |
| dc.source | https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/3223 | spa |
| dc.subject | Menopause | eng |
| dc.subject | Hormones | eng |
| dc.subject | Sexuality | eng |
| dc.subject | Effectivenes | eng |
| dc.subject | Safety | eng |
| dc.subject | Cardiovascular diseases | eng |
| dc.subject | Menopausia | spa |
| dc.subject | Hormonas | spa |
| dc.subject | Sexualidad | spa |
| dc.subject | Efectividad | spa |
| dc.subject | Seguridad | spa |
| dc.subject | Enfermedades Cardiovasculares | spa |
| dc.title | Influencia de la tibolona en la función sexual y seguridad cardiovascular en la mujer posmenopáusica | spa |
| dc.title.translated | Influence of tibolone on sexual function and cardiovascular safety in postmenopausal women | eng |
| dc.type | Artículo de revista | spa |
| dc.type.coar | http://purl.org/coar/resource_type/c_6501 | spa |
| dc.type.coarversion | http://purl.org/coar/version/c_970fb48d4fbd8a85 | spa |
| dc.type.content | Text | spa |
| dc.type.driver | info:eu-repo/semantics/article | spa |
| dc.type.local | Journal article | eng |
| dc.type.redcol | http://purl.org/redcol/resource_type/ARTREV | spa |
| dc.type.version | info:eu-repo/semantics/publishedVersion | spa |
| dspace.entity.type | Publication |
Sede: Claustro de San Agustín, Centro Histórico, Calle de la Universidad Cra. 6 #36-100
Colombia, Bolívar, Cartagena
Ver más...
